MP Court Denies Bail to Doctor in Contaminated Cough Syrup Case, Citing Prima Facie Guilt

CHHINDWARA, MADHYA PRADESH – A sessions court in Chhindwara has denied bail to a pediatrician, Dr. Praveen Soni, in a high-profile case involving the deaths of multiple children allegedly linked to a contaminated cough syrup. The court underscored the gravity of the offense and the existence of strong prima facie evidence against the accused, marking a critical juncture in a tragedy that has cast a harsh spotlight on India's pharmaceutical regulatory framework and the scope of medical liability.

Additional Sessions Judge Gautam Kumar Gujre, in the order for Dr Praveen Soni v State [BA No.: 99/2025] , dismissed the bail application, concluding that granting relief at this stage could jeopardize the ongoing investigation and potentially lead to witness tampering. The case revolves around "Coldrif" cough syrup, manufactured by Tamil Nadu-based Srisan (or Sresan) Pharmaceuticals, which was found to contain lethal levels of Diethylene Glycol (DEG), a toxic industrial solvent.

The court's decision hinges on its assessment of the preliminary evidence. The order states, "The evidence collected in the case discloses strong grounds for the offence alleged against the accused. As per the First Information Report... it has been prima facie found that other persons manufactured dangerous adulterated medicine which could cause death of a child and administered it to minor children with the knowledge of the same and also that the concerned prescription medicine was administered even after being aware of the incident".

The Prosecution's Case: Allegations of Knowledge and Financial Motive

Dr. Soni, a government pediatrician, faces charges under Section 276 of the Indian Penal Code (IPC) for knowingly selling a drug as a different one, and Section 27 of the Drugs and Cosmetics Act, 1940. The prosecution has constructed a narrative that goes beyond simple negligence, arguing that Dr. Soni was a culpable party with both knowledge and financial incentive.

Key allegations presented by the prosecution include: 1. Violation of Health Guidelines: The police report highlights that the Directorate General of Health Services (DGHS) had issued guidelines on December 18, 2023, advising against the prescription of certain fixed-dose combinations (FDCs) to children under the age of four. The prosecution alleges Dr. Soni prescribed Coldrif in direct contravention of this directive. 2. Financial Inducement: The police claim that Dr. Soni received a 10% commission for prescribing Coldrif syrup, suggesting a motive beyond patient care. This allegation is bolstered by the claim that a medical shop operated by his relatives, located adjacent to his private clinic, maintained a stock of the contentious syrup. 3. Continued Prescription After Harm: Perhaps the most damaging allegation is that Dr. Soni continued to prescribe the syrup even after initial reports of children suffering from severe adverse effects, including kidney failure, began to surface.

The court found these arguments compelling enough to deny bail, noting, "If the accused is granted the benefit of bail, the possibility of him influencing the prosecution witnesses cannot be ruled out."

The Defense: A Scapegoat for Systemic Failure?

Dr. Soni's defense counsel has vehemently argued that he is being falsely implicated and made a scapegoat for a catastrophic failure by the pharmaceutical manufacturer and government regulators. The defense contends that Dr. Soni, a doctor with a long-standing practice, was unaware that a specific batch of a government-approved drug was contaminated.

"He is a government pediatrician, and his only role was prescribing the medicine," the counsel argued. "The responsibility to inspect and test the medicine lies with the Drug Controller Department, not with the treating doctor."

This position has received robust support from the medical community. The Indian Medical Association (IMA) condemned Dr. Soni's arrest, asserting that "the culpability for introducing an adulterated drug into the market rests squarely with the manufacturer and the enforcement agencies." Medical associations have argued that blaming a prescribing doctor for a latent manufacturing defect sets a dangerous precedent, potentially leading to defensive medicine where doctors hesitate to prescribe even approved drugs.

Legal Implications and the Burden of 'Knowledge'

This case presents a complex legal challenge centered on the element of mens rea , or guilty knowledge. For a conviction under Section 276 IPC, the prosecution must prove that the accused knowingly sold or offered a drug as a different drug or preparation. The core legal battle will likely be fought over whether the prosecution can prove beyond a reasonable doubt that Dr. Soni was aware of the syrup's contamination or dangerous nature.

While the defense posits that a doctor cannot be expected to chemically analyze every prescribed medicine, the prosecution's allegations of commission payments and disregard for DGHS guidelines are aimed at establishing this very element of knowledge and intent. If proven, these facts could distinguish this case from a simple matter of professional negligence. The court’s prima facie acceptance of these grounds for the purpose of denying bail suggests the prosecution has presented a case that, at least at this preliminary stage, is considered substantial.

Broader Investigation and Regulatory Scrutiny

The tragedy has triggered a multi-pronged investigation. A Special Investigation Team (SIT) has been formed, and Govindan Ranganathan, the owner of Sresan Pharmaceuticals, has also been arrested. Furthermore, the Enforcement Directorate (ED) has initiated a money laundering probe, conducting raids at the company's premises in Chennai and the homes of drug control officials, signaling an inquiry into potential financial crimes and corruption within the regulatory apparatus.

The incident has also garnered international attention, with the World Health Organization (WHO) expressing "deep concern" over gaps in India's drug safety regulations. This tragedy follows similar incidents linked to Indian-made cough syrups in other countries, amplifying calls for systemic reforms in the country's pharmaceutical oversight mechanisms.

As the investigation remains incomplete, the Chhindwara court's decision to deny Dr. Soni bail reflects a judicial approach that prioritizes the integrity of the investigation in a case of immense public gravity. The ultimate outcome will have far-reaching implications, not only for the individuals involved but for defining the lines of accountability among doctors, pharmaceutical companies, and regulators in India's healthcare system.